The National Drug Abuse Treatment Clinical Trials Network
The National Drug Abuse Treatment Clinical Trials Network
批准号:
8660219
负责人:
WALTER NMN LING
金额:
$80.16万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-09-30 至 2015-08-31
关键词:
AddressAgonistBehavior TherapyBudgetsBuprenorphineClinicalClinical ResearchClinical Trials NetworkCollaborationsCommunitiesContractsCountryDA10DataData CollectionData QualityDevelopmentDoctor of MedicineDrug abuseEnsureEvaluationFundingHealth PersonnelHealth Services AccessibilityHepaticHuman ResourcesIndividualInternetLeadLeadershipManualsMeasuresMethadoneMethodsMissionModalityMonitorNaloxoneNational Institute of Drug AbuseNetwork-basedOutcomePacific NorthwestParticipantPatientsPerformancePersonsPharmaceutical PreparationsPopulationProcessProtocols documentationProviderPublic HealthPublicationsRandomizedRegulatory AffairsReplacement TherapyResearchResearch ActivityResearch InstituteResearch PersonnelResourcesSafetyScheduleScienceServicesSiteSubstance abuse problemSuicideTechnologyTestingTimeTimeLineTrainingTraining ActivityWorkaddictionbasecocaine usecommunity based treatmentcostimplementation researchimprovedinnovationmeetingsmembernamed groupprogramsprotocol developmentpublic health relevanceracial and ethnicscreeningsymposium
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Responding to RFA-DA-10-009, this application seeks renewal of the Pacific Region Node of the National Drug Abuse Treatment Clinical Trials Network (CTN) to continue improving the quality and delivery of addiction treatments that can be implemented efficiently by community-based treatment providers (CTPs). The ongoing and future research, training, and dissemination activities of the Pacific Region Node, led by Walter Ling, M.D., will serve the CTN mission "to improve the quality of drug abuse treatment throughout the country, using science as a vehicle." The Node will continue to contribute significantly to the CTN effort by its leadership and participation in innovative concept development, rigorous conduct of research, efficient management, and effective dissemination of CTN products. In the most recent funding period, for example, Node participants developed two protocols and currently lead protocol development of CTN0048, Cocaine Use Reduction with Buprenorphine (CURB). Node personnel will continue to develop and disseminate training materials and manuals for use across the CTN, to plan and host CTN-oriented conferences, and disseminate CTN-based findings through trainings, presentations, publications, and Internet-based methods. The Node's activities will advance the science and increase broad implementation of research-proven treatments in a collaborative manner with other nodes, CTN CTPs, and other providers and researchers worldwide. This renewal proposes adding two CTPs to the existing five, increasing geographic presence and racial/ethnic inclusion as well as ensuring access to every possible setting, modality, special population, and drug abuse problem. The Pacific Region Node intends to accelerate development and testing of new medications and behavioral therapies that can be integrated to achieve better outcomes. Innovation, research pacing, and relevance will be enhanced by increasing interaction with provider groups and with researchers examining potential therapies, exploiting the Node's existing partnerships while building new collaborations and involving more broad-based settings. Renewal of the Pacific Region Node will strengthen CTN efforts through collaborative work with NIDA, CTN participants, and other stakeholders.
PUBLIC HEALTH RELEVANCE: To promote use of research-proven addiction treatments, the Pacific Region Node will continue its work to incorporate more broad-based settings for CTN research, resulting in greater inclusion of and service to populations that are not comprehensively served by traditional CTPs. The Node will continue collaboration with the overall CTN to identify and address addiction challenges, public health needs, and research issues.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Sustained-Release Methylphenidate For Management of Methamphetamine Use Disorders
-
批准号:7762850
-
项目类别:
-
资助金额:$46.71万
-
财政年份:2009
-
负责人:WALTER NMN LING
-
依托单位:
Sustained-Release Methylphenidate For Management of Methamphetamine Use Disorders
-
批准号:7508842
-
项目类别:
-
资助金额:$44.69万
-
财政年份:2009
-
负责人:WALTER NMN LING
-
依托单位:
Sustained-Release Methylphenidate For Management of Methamphetamine Use Disorders
-
批准号:8250473
-
项目类别:
-
资助金额:$45.61万
-
财政年份:2009
-
负责人:WALTER NMN LING
-
依托单位:
Sustained-Release Methylphenidate For Management of Methamphetamine Use Disorders
-
批准号:8069996
-
项目类别:
-
资助金额:$46.2万
-
财政年份:2009
-
负责人:WALTER NMN LING
-
依托单位:
Optimizing Outcomes Using Suboxone for Opiate Dependence
-
批准号:7284221
-
项目类别:
-
资助金额:$48.99万
-
财政年份:2006
-
负责人:WALTER NMN LING
-
依托单位:
Optimizing Outcomes Using Suboxone for Opiate Dependence
-
批准号:7848882
-
项目类别:
-
资助金额:$49.03万
-
财政年份:2006
-
负责人:WALTER NMN LING
-
依托单位:
Optimizing Outcomes Using Suboxone for Opiate Dependence
-
批准号:7674507
-
项目类别:
-
资助金额:$49.08万
-
财政年份:2006
-
负责人:WALTER NMN LING
-
依托单位:
Optimizing Outcomes Using Suboxone for Opiate Dependence (R01 DA 020210-01)
-
批准号:7097067
-
项目类别:
-
资助金额:$51.77万
-
财政年份:2006
-
负责人:WALTER NMN LING
-
依托单位:
Optimizing Outcomes Using Suboxone for Opiate Dependence
-
批准号:7502046
-
项目类别:
-
资助金额:$49.04万
-
财政年份:2006
-
负责人:WALTER NMN LING
-
依托单位:
EFFECTS OF METHAMPHETAMINE ABUSE ON CEREVRAL GLUCOSE METABOLISM
-
批准号:7205342
-
项目类别:
-
资助金额:$0.17万
-
财政年份:2004
-
负责人:WALTER NMN LING
-
依托单位:
PAIN ANALGESIC RESPONSE IN OPIATE DEPENDENCE
-
批准号:6515826
-
项目类别:
-
资助金额:$53.04万
-
财政年份:2001
-
负责人:WALTER NMN LING
-
依托单位:
PAIN ANALGESIC RESPONSE IN OPIATE DEPENDENCE
-
批准号:6634332
-
项目类别:
-
资助金额:$50.34万
-
财政年份:2001
-
负责人:WALTER NMN LING
-
依托单位:
PAIN ANALGESIC RESPONSE IN OPIATE DEPENDENCE
-
批准号:6805899
-
项目类别:
-
资助金额:$9.53万
-
财政年份:2001
-
负责人:WALTER NMN LING
-
依托单位:
PAIN ANALGESIC RESPONSE IN OPIATE DEPENDENCE
-
批准号:6261234
-
项目类别:
-
资助金额:$55.78万
-
财政年份:2001
-
负责人:WALTER NMN LING
-
依托单位:
PHARMACOKINETICS AND BIOAVAILABILITY OF LIQUID VS. TABLET BUPRENORPHINE
-
批准号:6412136
-
项目类别:
-
资助金额:$20.73万
-
财政年份:2000
-
负责人:WALTER NMN LING
-
依托单位:
SAFETY EVALUATION OF LOFEXIDINE FOR THE TREATMENT OF OPIATE WITHDRAWAL
-
批准号:6412139
-
项目类别:
-
资助金额:$20.73万
-
财政年份:2000
-
负责人:WALTER NMN LING
-
依托单位:
NIDA CLINICAL TRIALS NETWORK: UCLA RESEARCH NODE
-
批准号:6523094
-
项目类别:
-
资助金额:$180.0万
-
财政年份:1999
-
负责人:WALTER NMN LING
-
依托单位:
The National Drug Abuse Treatment Clinical Trials Network
-
批准号:8134768
-
项目类别:
-
资助金额:$118.03万
-
财政年份:1999
-
负责人:WALTER NMN LING
-
依托单位:
The National Drug Abuse Treatment Clinical Trials Network
-
批准号:8610091
-
项目类别:
-
资助金额:$153.73万
-
财政年份:1999
-
负责人:WALTER NMN LING
-
依托单位:
The National Drug Abuse Treatment Clinical Trials Network
-
批准号:8800618
-
项目类别:
-
资助金额:$261.46万
-
财政年份:1999
-
负责人:WALTER NMN LING
-
依托单位:
国内基金
海外基金
Agonist-GPR119-Gs复合物的结构生物学研究
-
批准号:32000851
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:乔安娜
-
依托单位: